These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8834840)

  • 21. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
    Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
    Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
    Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
    Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour necrosis factor: clinical relevance.
    Jones AL; Selby P
    Cancer Surv; 1989; 8(4):817-36. PubMed ID: 2701729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
    Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
    Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms].
    Muc M; Baranowski M; Braczkowski R; Zubelewicz B; Kozowicz A
    Przegl Lek; 1996; 53(2):78-82. PubMed ID: 8754326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I clinical trial of recombinant human tumor necrosis factor.
    Creagan ET; Kovach JS; Moertel CG; Frytak S; Kvols LK
    Cancer; 1988 Dec; 62(12):2467-71. PubMed ID: 3191449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
    Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
    Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
    Chapman PB; Lester TJ; Casper ES; Gabrilove JL; Wong GY; Kempin SJ; Gold PJ; Welt S; Warren RS; Starnes HF
    J Clin Oncol; 1987 Dec; 5(12):1942-51. PubMed ID: 3681377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
    Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
    Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience of EET therapy for 75 advanced cancer patients.
    Kato M; Shinohara H; Goto S; Takagi K; Soma G
    Anticancer Res; 1998; 18(5D):3941-9. PubMed ID: 9854508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.
    Schiller JH; Storer BE; Witt PL; Alberti D; Tombes MB; Arzoomanian R; Proctor RA; McCarthy D; Brown RR; Voss SD
    Cancer Res; 1991 Mar; 51(6):1651-8. PubMed ID: 1998956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
    Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
    Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].
    Noda K; Hirabayashi K; Terashima Y; Ozaki M; Yakushiji M; Hatae M; Kanazawa K
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1285-93. PubMed ID: 9279348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients.
    Tonini G; Santini D; Vincenzi B; Borzomati D; Dicuonzo G; La Cesa A; Onori N; Coppola R
    J Biol Regul Homeost Agents; 2002; 16(2):105-9. PubMed ID: 12144121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
    Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.